Miniatura

Fitxers

920833.pdf (1.41 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-12-03

Llicència de publicació

cc-by (c) Escudero, Alicia et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227110

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ctrv.2025.103063

Resum

Background: Several endocrine-based strategies have been evaluated following CDK4/6 inhibition (CDK4/6i) in hormone receptor-positive advanced breast cancer. However, the absence of head-to-head comparisons leave uncertainty regarding the optimal treatment selection. Methods: A systematic literature search was performed to identify randomized controlled trials (RCTs) evaluating endocrine-based strategies after CDK4/6i for hormone receptor-positive advanced breast cancer. A network meta-analysis was used to compare overall treatment strategies, rather than individual treatments. In addition, an extracted individual patient data meta-analysis was conducted. The primary endpoint was progression-free survival (PFS) evaluated independently in tumors with PI3K-AKT-PTEN alterations, ESR1-mutated and wild-type tumors. Results: A total of 20 RCTs including 4,716 patients were included. In ESR1-mutated tumors, oral SERD/SERM/PROTAC showed numerically better PFS compared with switching CDK4/6i plus fulvestrant (HR = 0.67, 95 % CI 0.45-1.00). In this population, the addition of i) CDK4/6i or ii) mTORi to oral SERDs improved PFS compared with oral SERD/SERM/PROTAC alone (HR = 0.44, 95 % CI 0.27-0.72 and HR = 0.45, 95 % CI 0.23-0.89, respectively). In PI3K-AKT-PTEN altered tumors, the greatest benefit was observed with PI3K/AKT/mTORi plus fulvestrant and oral SERDs plus CDK4/6i (P-scores > 0.75). In ESR1 and PI3K/AKT/PTEN wild-type tumors, several treatment combinations outperformed fulvestrant. The use of PI3K/AKT/mTORi plus fulvestrant was associated with the highest incidence of grade ≥ 3 adverse events (66.0 %). Conclusion: This meta-analysis reinforces the importance of molecular stratification in treatment decisions after CDK4/6i progression, highlighting the need for efficacy and safety assessments across biomarker-selected subgroups.

Matèries

Oncologia, Càncer de mama, Ginecologia endocrina

Matèries (anglès)

Oncology, Breast cancer, Endocrine gynecology

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ESCUDERO, Alicia, BELLET, Meritxell, SAURA, Cristina, AGUILERA, Anna, PAPAKONSTANTINOU, Andri, TOLOSA, Pablo, GARCÍA-SÁENZ, José ángel, MORENO, Fernando, LÓPEZ DE SÁ, Alfonso, SCHETTINI, Francesco, SEGUÍ, Elia, GONZÁLEZ RODRÍGUEZ, Marta, NAVARRO, Victor, FERRERO-CAFIERO, Juan manuel, GONZÁLEZ, Xavier, HERNANDO, Cristina, MATIKAS, Alexios, PRAT APARICIO, Aleix, OLIVEIRA, Mafalda, PASCUAL, Tomás, VILLACAMPA, Guillermo. Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis. _Cancer Treatment Reviews_. 2025. Vol. 142. [consulta: 7 de abril de 2026]. ISSN: 0305-7372. [Disponible a: https://hdl.handle.net/2445/227110]

Exportar metadades

JSON - METS

Compartir registre